Ahmed Goran A, Baron Daniel H, Agrawal Amit
Frimley Park Hospital, Frimley Health NHS Foundation Trust, Camberley, UK.
John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, UK.
Breast Cancer Res Treat. 2025 Jan;209(2):229-252. doi: 10.1007/s10549-024-07566-6. Epub 2024 Dec 14.
Oncoplastic breast-conserving surgery (OBCS) prevents compromise of breast aesthetics following large breast cancer excisions. This systematic review was conducted to investigate the outcomes (oncologic, surgical, cosmetic) of OBCS versus standard breast-conserving surgery (SBCS) and mastectomy post-neo-adjuvant systemic therapy.
Ovid, Web of Science, Cochrane, ClinicalTrials.gov databases were searched up to 24/08/2024. English language peer-reviewed RCTs or observational/cohort studies with ≥ 18-year-old women treated for breast cancer with neoadjuvant chemotherapy (NACT) and/or hormonal therapy comparing OBCS to SBCS and/or mastectomy were included. Of 6794 articles, 32 underwent full-text assessment and eleven met the inclusion criteria. The review was conducted using PRISMA guidelines. Two reviewers independently extracted data and assessed risk of bias (Newcastle-Ottowa Scale). Meta-analysis using a random-effects model were performed where data allowed.
Eleven cohort studies (n = 4594) included OBCS (n = 912), SBCS (n = 1122) and mastectomy (n = 2560) after NACT. Post-NACT tumour size was 20(9-44) mm, 13(0-23)mm [SMD 0.62, 95%CI(-0.24,1.48), p = 0.16] and 20(10-31)mm [SMD 0.05, 95%CI(-0.53,0.63), p = 0.86] in the OBCS, SBCS and mastectomy groups respectively. The margin re-excision rate was significantly lower in OBCS than in SBCS [2.9%(0-11.1%) vs. 6.1%(0-18.5%); OR 0.35, 95%CI(0.15,0.80), p = 0.01]. All other oncologic outcomes, including positive margin rate, and overall survival, were not statistically different between the groups. Cosmetic outcomes and patient-reported outcome measures were marginally in favour of OBCS [OBCS 50-66% vs SBCS 37.6-55% very satisfied].
OBCS after NACT appears oncologically safe and a potential alternative in patients with partial or poor tumour response to NACT. Further studies are required, directly comparing well-matched OBCS with SBCS and mastectomy patients after NACT.
肿瘤整形保乳手术(OBCS)可防止在切除较大乳腺癌后影响乳房美观。本系统评价旨在研究OBCS与标准保乳手术(SBCS)以及新辅助全身治疗后乳房切除术的疗效(肿瘤学、手术、美容方面)。
检索截至2024年8月24日的Ovid、科学网、Cochrane、ClinicalTrials.gov数据库。纳入英语同行评审的随机对照试验(RCT)或观察性/队列研究,研究对象为年龄≥18岁、接受新辅助化疗(NACT)和/或激素治疗的乳腺癌女性,比较OBCS与SBCS和/或乳房切除术。在6794篇文章中,32篇进行了全文评估,11篇符合纳入标准。本评价按照PRISMA指南进行。两名评审员独立提取数据并评估偏倚风险(纽卡斯尔-渥太华量表)。在数据允许的情况下,使用随机效应模型进行荟萃分析。
11项队列研究(n = 4594)纳入了NACT后的OBCS(n = 912)、SBCS(n = 1122)和乳房切除术(n = 2560)。NACT后,OBCS组、SBCS组和乳房切除术组的肿瘤大小分别为20(9 - 44)mm、13(0 - 23)mm [标准化均数差(SMD)0.62,95%置信区间(CI)(-0.24,1.48),p = 0.16]和20(10 - 31)mm [SMD 0.05,95%CI(-0.53,0.63),p = 0.86]。OBCS组的切缘再次切除率显著低于SBCS组[2.9%(0 - 11.1%)对6.1%(0 - 18.5%);比值比(OR)0.35,95%CI(0.15,0.80),p = 0.01]。其他所有肿瘤学结局,包括切缘阳性率和总生存率,在各组之间无统计学差异。美容结局和患者报告的结局指标略微倾向于OBCS [OBCS组50 - 66% vs SBCS组37.6 - 55%非常满意]。
NACT后的OBCS在肿瘤学上似乎是安全的,对于NACT部分反应不佳或反应较差的患者可能是一种替代选择。需要进一步研究,直接比较NACT后匹配良好的OBCS患者与SBCS和乳房切除术患者。